Exploring Updates on AMPLIFY at ASH 2024

In separate, live virtual events, Alvaro Jose Alencar, MD, and Michael E. Williams, MD, discussed third-line options for a patient with relapsed/refractory chronic lymphocytic leukemia (CLL).

Current frontline treatment options for patients with chronic lymphocytic leukemia have grown over the past year, specifically with the approval of zanubrutinib.

Real-world data suggest optimal CLL/SLL treatment sequencing involves targeted therapies, including covalent BTKis and BCL2 inhibitors, for better survival outcomes.

In season 4, episode 7 of Targeted Talks, Cyrus M. Khan, MD, discusses the latest FDA activity in the chronic lymphocytic leukemia space.

The novel Bruton tyrosine kinase degrader BGB-16673 shows promise in relapsed/refractory Waldenström macroglobulinemia previously exposed to BTK inhibitors, and in heavily pretreated patients with R/R chronic lymphocytic leukemia/small lymphocytic lymphoma.

Pirtobrutinib, a third-generation BTK inhibitor, showed superior progression-free survival and lower treatment discontinuation rates vs investigator's choice in previously treated CLL/SLL.